A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Medicine, Cardiology, Pathology +15

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

Giovanni Palladini, Angela Dispenzieri, Morie A. Gertz et al. · Journal of Clinical Oncology · 2012 · 969 citations

Medicine, Cardiology, Hematology +17

A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine

Robert A. Kyle, Morie A. Gertz, Philip R. Greipp et al. · New England Journal of Medicine · 1997 · 691 citations · Full text

Medicine, Clinical Sciences, Neurology +14

Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis

Giovanni Palladini, Carlo Campana, Catherine Klersy et al. · Circulation · 2003 · 519 citations · Full text

Medicine, Cardiology, Internal Medicine +11

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

Arnaud Jaccard, Philippe Moreau, Véronique Leblond et al. · New England Journal of Medicine · 2007 · 518 citations

Medicine, Hematology, Oncology +14